Pfm Health Sciences, LP Puma Biotechnology, Inc. Transaction History

Pfm Health Sciences, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$6.5 - $10.73 $24 Million - $39.6 Million	-3,689,538 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$8.75 - $12.85 $7.45 Million - $10.9 Million	851,162 Added 29.99%	3,689,538 $39.7 Million
Q2 2019 Aug 14, 2019	BUY	$12.3 - $35.76 $2.88 Million - $8.38 Million	234,456 Added 9.0%	2,838,376 $36.1 Million
Q1 2019 May 15, 2019	BUY	$20.77 - $42.37 $54.1 Million - $110 Million	2,603,920 New	2,603,920 $101 Million
Q4 2018 Feb 14, 2019	SELL	$20.07 - $46.7 $37.2 Million - $86.5 Million	-1,851,638 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$41.2 - $59.85 $10.5 Million - $15.3 Million	254,855 Added 15.96%	1,851,638 $84.9 Million
Q2 2018 Aug 14, 2018	SELL	$48.3 - $68.25 $21.1 Million - $29.7 Million	-435,836 Reduced 21.44%	1,596,783 $94.5 Million
Q1 2018 May 15, 2018	BUY	$59.7 - $99.25 $12.6 Million - $20.9 Million	210,819 Added 11.57%	2,032,619 $138 Million
Q4 2017 Feb 14, 2018	BUY	$93.85 - $132.45 $42.4 Million - $59.9 Million	452,221 Added 33.02%	1,821,800 $180 Million
Q3 2017 Nov 14, 2017	BUY	$72.0 - $119.75 $98.6 Million - $164 Million	1,369,579	1,369,579 $164 Million

102

29.1M

60.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $132M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Pfm Health Sciences, LP, based on Form 13F filings with the SEC.

Stay updated on Pfm Health Sciences, LP with notifications on news.